WAVE Life Sciences Aktie
WKN DE: A1436W / ISIN: SG9999014716
|
01.10.2026 16:44:32
|
Wave Gains FDA Support For WVE-006 Registrational Pathway In AATD
(RTTNews) - On Thursday, Wave Life Sciences (WVE) said it reached alignment with the FDA on key aspects of the registrational pathway for WVE-006, an investigational RNA editing therapy for alpha-1 antitrypsin deficiency (AATD).
WVE-006 is a GalNAc-conjugated, subcutaneously delivered RNA editing oligonucleotide designed to correct the RNA mutation associated with the Pi*ZZ genotype, potentially increasing healthy M-AAT and reducing mutant Z-AAT accumulation in the liver.
Wave plans a single two-year registrational trial to support potential full approval, with a one-year interim analysis that could support accelerated approval based on AATD biomarkers. The FDA also supports use of Wave's current LC-MS assay to measure M-AAT and Z-AAT protein.
WVE-006 is currently being evaluated in the Phase 1b/2a RestorAATion-2 trial. Wave expects to report data from the 600 mg monthly multidose cohort in the fourth quarter of 2026. The company said WVE-006 continues to be generally safe and well tolerated, with no liver toxicities reported.
Currently, WVE is trading at $3.95, up 6.89%.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu WAVE Life Sciences Ltd
| Keine Nachrichten verfügbar. |